Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H23NO3.BrH |
| Molecular Weight | 418.324 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.O=C(CCN1CCC(C1)C2=CC=CC=C2)C3=CC4=C(OCCO4)C=C3
InChI
InChIKey=YRTLMJNPRCWOML-UHFFFAOYSA-N
InChI=1S/C21H23NO3.BrH/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16;/h1-7,14,18H,8-13,15H2;1H
Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Pirroksan Approved UseProroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis. |
|||
| Primary | Pirroksan Approved UseProroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis. |
|||
| Primary | Pirroksan Approved UseProroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis. |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
J48JGW5NHZ
Created by
admin on Sat Dec 16 10:17:46 GMT 2023 , Edited by admin on Sat Dec 16 10:17:46 GMT 2023
|
PRIMARY | |||
|
51758-99-7
Created by
admin on Sat Dec 16 10:17:46 GMT 2023 , Edited by admin on Sat Dec 16 10:17:46 GMT 2023
|
PRIMARY | |||
|
119057589
Created by
admin on Sat Dec 16 10:17:46 GMT 2023 , Edited by admin on Sat Dec 16 10:17:46 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
